FDA Grants Rolling Review and CNPV Designation to Compass Pathways for TRD Treatment
The FDA has granted Compass Pathways (CMPS) a rolling review and CNPV designation for its psychedelic treatment COMP360 for treatment-resistant depression (TRD). This designation could significantly shorten the review timeline for the drug's approval, supported by positive Phase 3 trial data showing rapid and lasting clinical effects.
Tickers: $CMPS
Topics: CNPV Designation COMP360 Compass Pathways FDA Rolling Review Treatment-Resistant Depression